BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 9382047)

  • 21. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study.
    Fargion S; Fracanzani AL; Rossini A; Borzio M; Riggio O; Belloni G; Bissoli F; Ceriani R; Ballarè M; Massari M; Trischitta C; Fiore P; Orlandi A; Morini L; Mattioli M; Oldani S; Cesana B; Fiorelli G
    Am J Gastroenterol; 2002 May; 97(5):1204-10. PubMed ID: 12014729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance.
    Rocha CM; Perez RM; Narciso JL; Ferreira AP; Lemos LB; Medina-Pestana JO; Silva AE; Ferraz ML
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):119-23. PubMed ID: 17272996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Late disappearance of hepatitis C virus RNA from peripheral blood mononuclear cells in patients with chronic hepatitis C in sustained response after alpha-interferon therapy.
    García-Bengoechea M; Basaras M; Barrio J; Arrese E; Montalvo II; Arenas JI; Cisterna R
    Am J Gastroenterol; 1999 Jul; 94(7):1902-5. PubMed ID: 10406257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Relationship between diversity of hepatitis C virus quasispecies and viremia, activity of liver disease and response to interferon therapy].
    Tang X; Qian K; Yuan X; Johnson YN
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Jun; 16(2):128-31. PubMed ID: 12196822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of serologically silent occult hepatitis C virus infection by detecting immunoglobulin G antibody to a dominant HCV core peptide epitope.
    Quiroga JA; Castillo I; Llorente S; Bartolomé J; Barril G; Carreño V
    J Hepatol; 2009 Feb; 50(2):256-63. PubMed ID: 19070391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of anti-HCV IgM antibodies in patients with chronic hepatitis C treated with interferon.
    Picciotto A; Icardi G; Bardellini E; Borro P; Borzone S; Pireddu M; Sinelli N; Pezzano D; Orione L; Di Giacomo C
    Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):623-5. PubMed ID: 8590156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of specific antibodies to F protein in serum samples from Chinese hepatitis C patients treated with interferon plus ribavarin.
    Gao DY; Zhang XX; Hou G; Jin GD; Deng Q; Kong XF; Zhang DH; Ling Y; Yu DM; Gong QM; Zhan Q; Yao BL; Lu ZM
    J Clin Microbiol; 2008 Nov; 46(11):3746-51. PubMed ID: 18832124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical impact of genotype 1 TT virus infection in patients with chronic hepatitis C and response of TT virus to alpha-interferon.
    Nishizawa Y; Tanaka E; Orii K; Rokuhara A; Ichijo T; Yoshizawa K; Kiyosawa K
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1292-7. PubMed ID: 11129224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders.
    Brillanti S; Foli M; Di Tomaso M; Gramantieri L; Masci C; Bolondi L
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):130-4. PubMed ID: 10363198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.
    Bargiggia S; Thorburn D; Anderloni A; Ardizzone S; Giorgi A; Bianchi Porro G; Parente F
    Aliment Pharmacol Ther; 2005 Aug; 22(3):209-15. PubMed ID: 16091058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.
    Kawai S; Yokosuka O; Imazeki F; Saisho H; Mizuno C
    J Med Virol; 2002 Nov; 68(3):343-51. PubMed ID: 12226820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HCV-RNA and anti-HCV IgM in Egyptian subjects bearing IgG anti-HCV antibodies.
    el-Gohary A; Hosny AM; Fawaz N; Heiba A; Abdalla E; Kawano F; Kiyokawa T
    Jpn J Infect Dis; 1999 Jun; 52(3):113-6. PubMed ID: 10507990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative analysis of antibodies to hepatitis C virus during interferon-alpha therapy.
    Yuki N; Hayashi N; Hagiwara H; Takehara T; Katayama K; Kasahara A; Fusamoto H; Kamada T
    Hepatology; 1993 Jun; 17(6):960-5. PubMed ID: 7685734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
    Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
    Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
    Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
    De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
    Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical significance of IgM anti-HCV determination in chronic hepatitis C].
    Stránský J; Krtek V; Honzáková E; Vandasová J; Mand'áková Z; Kyncl J; Nĕmecek V
    Cas Lek Cesk; 1996 Apr; 135(7):215-9. PubMed ID: 8681370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IgM antibody response to the hepatitis C virus core protein in intravenous drug users.
    Toniutto P; Falleti E; Gasparini V; Fabris C; Tisminetzky SG; Lombardelli T; Pacco P; Satta A; Pirisi M
    Diagn Microbiol Infect Dis; 1999 Feb; 33(2):69-73. PubMed ID: 10091028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.